info@marketresearchfuture.com   📞  +1 (855) 661-4441(US)   📞  +44 1720 412 167(UK)
Certified Global Research Member
Isomar fd.webp Wcrc 57.webp
Key Questions Answered
  • Global Market Outlook
  • In-depth analysis of global and regional trends
  • Analyze and identify the major players in the market, their market share, key developments, etc.
  • To understand the capability of the major players based on products offered, financials, and strategies.
  • Identify disrupting products, companies, and trends.
  • To identify opportunities in the market.
  • Analyze the key challenges in the market.
  • Analyze the regional penetration of players, products, and services in the market.
  • Comparison of major players’ financial performance.
  • Evaluate strategies adopted by major players.
  • Recommendations
Why Choose Market Research Future?
  • Vigorous research methodologies for specific market.
  • Knowledge partners across the globe
  • Large network of partner consultants.
  • Ever-increasing/ Escalating data base with quarterly monitoring of various markets
  • Trusted by fortune 500 companies/startups/ universities/organizations
  • Large database of 5000+ markets reports.
  • Effective and prompt pre- and post-sales support.

Sentinel Node Biopsy Market Size

ID: MRFR//4133-CR | 128 Pages | Author: Rahul Gotadki| January 2024

The dynamics of the SENTINEL NODE BIOPSY market are closely encouraged by the growing occurrence and prevalence rates of cancers, specifically breast cancer and melanoma, where this diagnostic process is generally carried out. As those fees continue to thrust upward, there's a growing demand for accurate and minimally invasive techniques of most cancer staging, using the market for Sentinel Node Biopsy. Ongoing improvements in imaging technologies make contributions notably to the increase of the SENTINEL NODE BIOPSY marketplace. Improved imaging modalities, consisting of lymphoscintigraphy and gamma probe detection, enhance the precision and reliability of the method. Market players investing in modern technologies are better located to meet the evolving needs of healthcare professionals. Evolving developments in cancer control, emphasizing early detection and personalized treatment methods, impact the SENTINEL NODE BIOPSY market. This system allows for particular identification and examination of the first lymph nodes draining a tumor, aiding in correct staging and treatment-making plans.
The reimbursement landscape plays an essential role in the adoption of Sentinel Node Biopsy. Changes in reimbursement guidelines and healthcare economics can impact the decision-making process for both healthcare providers and patients. Market stakeholders need to be knowledgeable about compensation trends to navigate this component of the market successfully. Patient advocacy businesses and recognition campaigns contribute to the knowledge and acceptance of Sentinel Node Biopsy among individuals liable to or diagnosed with certain cancers. Market participants conducting collaborative efforts with advocacy agencies might also experience multiplied patient demand for the process, in particular in instances in which Sentinel Node Biopsy is recommended as part of the usual care. The regulatory panorama notably affects the development and advertising of medical devices, including the ones utilized in Sentinel Node Biopsy. Adhering to regulatory requirements and successfully navigating approval strategies is critical for marketplace players. Understanding the regulatory panorama guarantees well-timed marketplace entry and compliance with enterprise standards.
The SENTINEL NODE BIOPSY marketplace is characterized by competition amongst manufacturers striving for technological innovation and marketplace proportion. Mergers, acquisitions, and collaborations are commonplace techniques for corporations aiming to bolster their positions. An understanding of the aggressive panorama is crucial for predicting market tendencies and waiting for future developments. The price-effectiveness of Sentinel Node Biopsy in comparison to alternative diagnostic strategies is a sizable issue influencing marketplace dynamics. As healthcare systems pay global attention to fee containment, market gamers developing solutions that balance effectiveness with affordability are probably to revel in sustained demand for their products within the evolving landscape of most cancer diagnostics.

Covered Aspects:

Report Attribute/Metric Details
Market Size Value In 2023 USD 0.683 Billion
Growth Rate 4.41% (2024-2032)

Global Sentinel Node Biopsy Market Overview


The Sentinel Node Biopsy Market size was valued at USD 0.683 Billion in 2023 and is projected to grow from USD 0.717 Billion in 2024 to USD 1.012 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 4.41% during the forecast period (2024 - 2032). Increasing incidences of cancer globally, Launch & approval of innovative products, and increasing global aging population are driving the market growth.


Sentinel Node Biopsy Market


Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review


Sentinel Node Biopsy Market Trends



  • Increasing incidences of cancer globally to boost the market growth


The Sentinel Node Biopsy (SNB) has been utilized frequently in several cancers, namely breast, melanoma, and the oral cavity among others. The SNB assists the physician in determining if breast cancer or melanoma has spread beyond the original tumor. Sentinel node biopsy is a minimally invasive procedure that helps determine whether cancer has spread to the lymph nodes, providing crucial information for treatment planning. With more cancer cases being diagnosed, the demand for sentinel node biopsy as a reliable staging tool is expected to increase. The increasing prevalence of breast cancer is fueling the demand for sentinel node biopsies.


In February 2023, the World Health Organization reported that approximately 2.3 million cases of breast cancer occur each year, mostly among adults. Furthermore, breast cancer is the first or second leading cause of death in approximately 95% of countries worldwide. Moreover, as per the International Agency for Research on Cancer, there were 325, 000 new diagnosed cases of melanoma globally in 2020. Also, the highest rate has been found in Australia and New Zealand, followed by Western Europe, Northern America, and Northern Europe. Additionally, there were 377,713 new cases diagnosed with oral cancer worldwide in 2020, and physicians are majorly using SNB for oral cancer for the detection of lymph nodes.


Therefore, increasing incidences of above-mentioned cancer and high demand for SNB for the same are propelling the sentinel node biopsy market's growth.


Sentinel Node Biopsy Market Segment Insights


Sentinel Node Biopsy Type Insights


The Sentinel Node Biopsy Market segmentation, based on Product Type, includes Breast Localization Wire, Biopsy System, Tissue Marker, Gamma Probe, Drainage Catheters, Others. The Biopsy System segment is to hold the majority share in 2022 in the Sentinel Node Biopsy Market revenue. This is because advancements in biopsy systems and a surge in demand for accurate cancer diagnosis. Technological innovations, such as enhanced imaging resolution and the integration of multimodal approaches, are creating opportunities for more precise and reliable procedures. The rise of personalized medicine and targeted therapies further underscores the importance of sentinel node biopsy in guiding tailored treatment plans.


Sentinel Node Biopsy Technology Insights


The Sentinel Node Biopsy Market segmentation is based on a Technology, that includes SPECT Technology, SPY Fluorescence Imaging Technology, Others. The SPY Fluorescence Imaging Technology segment has dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2023-2032. This is due to an innovative approach that enhances the precision of sentinel node biopsy procedures, providing real-time visualization and improved accuracy in identifying lymph nodes. SPY fluorescence imaging contributes to the expansion of the biopsy system landscape, offering enhanced sensitivity and specificity.


Sentinel Node Biopsy Indication Insights


The Sentinel Node Biopsy Market segmentation is based on an Indication, that includes Breast Cancer, Melanoma, Colon Cancer, Esophageal Cancer, Others. The Breast Cancer indication segment has dominated the market in 2022 and is projected to be the fastest-growing segment during the forecast period, 2023-2032. This is due to breast cancer remaining a prevalent global health concern, sentinel node biopsy plays a crucial role in providing accurate staging information. The integration of cutting-edge technologies, including SPY fluorescence imaging, enhances the precision of these procedures, contributing to improved patient outcomes. The increasing incidence of breast cancer worldwide underscores the importance of early detection, and sentinel node biopsy, with its evolving techniques and technologies, stands at the forefront of ensuring effective diagnosis and personalized treatment strategies, thereby driving the growth of the global market.


Figure 2: SENTINEL NODE BIOPSY MARKET, BY INDICATION, 2022 & 2032 (USD Billion)


SENTINEL NODE BIOPSY MARKET, BY INDICATION, 2022 & 2032


Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review


Sentinel Node Biopsy End User Insights


The Sentinel Node Biopsy Market segmentation is based on end-user that Hospitals and Clinics, Diagnostic Center, Others. The hospitals and clinics segment has dominated the market in 2022 and homecare is projected to be the fastest-growing segment during the forecast period, 2023-2032. This is due to growing emphasis on comprehensive cancer care, which is driving the demand for sentinel node biopsy, ensuring timely and precise diagnoses. This trend reflects a broader commitment to enhancing patient outcomes and aligns with the evolving landscape of global healthcare practices.


Sentinel Node Biopsy Regional Insights


By Region, the study segments the market into North America, Europe, Asia-Pacific, and the Rest of the World. The North American Sentinel Node Biopsy market accounted for the largest market share in 2022due to increasing awareness, technological advancements, and a proactive approach to cancer diagnosis. With a focus on improving patient outcomes, the region's healthcare institutions are embracing sentinel node biopsy procedures, particularly in the context of breast cancer diagnosis. Advanced biopsy systems and technologies like SPY fluorescence imaging are playing a crucial role in enhancing the accuracy and efficiency of these procedures. The rising incidence of cancer, coupled with the region's commitment to cutting-edge healthcare practices, positions North America at the forefront of the Sentinel Node Biopsy Market, fostering innovation and comprehensive cancer care.


Further, the major countries studied are the U.S., Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.


Figure 3: SENTINEL NODE BIOPSY MARKET BY REGION 2022 & 2032


SENTINEL NODE BIOPSY MARKET BY REGION 2022 & 2032


Source: Secondary Research, Primary Research, MRFR Database, and Analyst Review


Europe Sentinel Node Biopsy market is expected to account for the second-largest market share due to the favorable health policies and trend towards integrating health services, including counseling. Further, the German Sentinel Node Biopsy market was attributed to holding the largest market share, and France Sentinel Node Biopsy market is expected to fastest-growing market in the European region.


The Asia-Pacific healthcare counseling market is expected to grow at the fastest rate from 2024 to 2032. This is due to the rising spending in healthcare, quickly evolving healthcare infrastructure, growing awareness regarding Sentinel Node Biopsy, and growing population in the region. Moreover, China’s Sentinel Node Biopsy market is expected to hold the largest market share, and India Sentinel Node Biopsy market is expected fastest-growing market in the Asia-Pacific region.


The Rest of the World includes the Middle East, Africa, and Latin America. The main factors influencing the growth of Sentinel Node Biopsy in the Middle East and Africa. Increasing awareness and advancements in cancer diagnostic technologies. As healthcare infrastructures continue to develop in the region, there's a rising emphasis on precise cancer staging, positioning sentinel node biopsy as a crucial procedure.


Sentinel Node Biopsy Key Market Players & Competitive Insights


The Sentinel Node Biopsy Market is characterized by the presence of many global, regional, players. The market comprises tier-1, tier-2, and local players. The tier-1 and tier-2 players have reached across the globe with diverse Type portfolios. Companies such as BD (US), Stryker (US), Boston Scientific Corporation (US), Hologic, Inc (US), KUB Technologies (US) are dominate the Sentinel Node Biopsy Market due to Type differentiation, financial stability, strategic services, and diversified regional presence. The players are focused on investing in extensive research and development as well. Furthermore, they adopt strategic growth initiatives, such as expansion, joint ventures, and partnerships, to strengthen their market position and capture a large customer base.


One of the primary business strategies adopted by manufacturers in the global Sentinel Node Biopsy industry to benefit clients and expand the healthcare counseling market sector is to manufacture locally to reduce operating costs.


Key Companies in the Sentinel Node Biopsy Market include



  • BD (US)

  • Stryker (US)

  • Boston Scientific Corporation (US)

  • KUB Technologies (US)

  • Care Wise (UK)

  • Hologic, Inc (US)

  • SurgicEye GmbH (Germany)

  • Intramedical Imaging, LLC (US)

  • Navidea Biopharmaceuticals, Inc (US)

  • Devicor Medical Products, Inc (US)


Sentinel Node Biopsy Industry Developments


In April 2022, KUBTEC® Medical Imaging (US) unveiled the market's most advanced wireless sentinel lymph node localization technology. The new KUBTEC gamma detection system redefines gamma probe performance with its modern design, high sensitivity, dependable Bluetooth, and sterilization capabilities.


In January 2020, BD (US) acquired Straub Medical AG, a Swiss company that develops and manufactures biopsy systems. This acquisition expands BD's portfolio of breast biopsy products and strengthens its position in the market.


Sentinel Node Biopsy Market Segmentation


Sentinel Node Biopsy Product Type Outlook



  • Breast Localization Wire

  • Biopsy System

  • Tissue Marker

  • Gamma Probe

  • Drainage Catheters

  • Others


Sentinel Node Biopsy Technology Outlook



  • SPECT Technology

  • SPY Fluorescence Imaging Technology

  • Others


Sentinel Node Biopsy Indication Outlook



  • Breast Cancer

  • Melanoma

  • Colon Cancer

  • Esophageal Cancer

  • Others


Sentinel Node Biopsy End User Outlook



  • Hospitals and Clinics

  • Diagnostic Center

  • Others


Sentinel Node Biopsy Regional Outlook



  • North America

    • US

    • Canada



  • Europe

    • Germany

    • France

    • UK

    • Italy

    • Spain

    • Rest of Europe



  • Asia-Pacific

    • China

    • Japan

    • India

    • Australia

    • South Korea

    • Rest of Asia-Pacific



  • Rest of the World

    • Middle East

    • Africa

    • Latin America



Leading companies partner with us for data-driven Insights
client_1 client_2 client_3 client_4 client_5 client_6 client_7 client_8 client_9 client_10
Kindly complete the form below to receive a free sample of this Report
Please fill in Business Email for Quick Response

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Purchase Option
Single User $ 4,950
Multiuser License $ 5,950
Enterprise User $ 7,250
Compare Licenses
Tailored for You
  • Dedicated Research on any specifics segment or region.
  • Focused Research on specific players in the market.
  • Custom Report based only on your requirements.
  • Flexibility to add or subtract any chapter in the study.
  • Historic data from 2014 and forecasts outlook till 2040.
  • Flexibility of providing data/insights in formats (PDF, PPT, Excel).
  • Provide cross segmentation in applicable scenario/markets.